The Efficacy and Safety of Subcutaneous Tetrodotoxin (Tectin™) for Moderate to Severe Inadequately Controlled Cancer-Related Pain - No Study Results Posted

The Efficacy and Safety of Subcutaneous Tetrodotoxin (Tectin™) for Moderate to Severe Inadequately Controlled Cancer-Related Pain (TEC-006)

This study is currently recruiting participants.

Study NCT00725114 Information provided by Wex Pharmaceuticals Inc.

First Received: July 28, 2008 Last Updated: April 30, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)